Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma

Multiple myeloma (MM) is a rare neoplastic disorder characterized by uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM). In the last decade, the therapeutic approaches to treat MM patients have been improved. Nevertheless, the urgent need to identify new therapeutic targets remains to develop more effective strategies against this uncurable disease. … Continued

Biomarkers for monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

In this collaborative research project, we aim to identify and develop blood biomarkers improving MGUS follow-up. To achieve this, blood-based proteomic analysis using untargeted i3-D/LC mass spectrometry in unique prospective longitudinal blood samples (n=880) collected in participants of the Northern Sweden Health and Disease Study (UmeÃ¥ University, Sweden) is performed. Routine and novel biomarkers will … Continued

Ancestrality of genomic alterations in Multiple Myeloma: impact on the clonal evolution and on the Minimal Residual Disease dynamics

Copy Number Alterations (CNAs) play a key role in the Multiple Myeloma (MM) pathogenesis and prognostic stratification of the disease. For this reason, it is of particular biological and clinical interest to study the temporal occurrence of early alterations over the developmental history of MM. This, in order to identify specific altered chromosomal regions or … Continued

Optimizing Melphalan dose among older adults with Multiple Myeloma receiving Autologous Stem Cell Transplantation

This research project focuses on optimizing melphalan dosing for older adults undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM). While ASCT with high-dose melphalan is effective, older adults are at increased risk of severe toxicities, impacting their quality of life. Currently, there’s uncertainty about the appropriate melphalan dose for older adults, with many … Continued

Evaluation of single nucleotide polymorphisms of BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with clinical outcomes

Autologous Stem Cell Transplantation represents a widely accessible therapy in Latin America, particularly crucial given the limited availability of new medications in the region, including monoclonal antibodies, next-generation proteasome inhibitors, immunomodulators, and advanced cellular therapies. This study aims to assess the impact of the genetic profile, particularly single nucleotide variants (SNVs), on the clinical outcomes … Continued

Investigating the molecular mechanisms of microenvironment-dependent immune escape to natural killer cells in myeloma to uncover biomarkers for rational combination treatment strategie

The research project aims to understand the molecular mechanisms behind microenvironment-dependent immune escape to natural killer (NK) cells in myeloma, with the goal of identifying biomarkers for rational combination treatment strategies. Aim 1 involves validating candidate markers of NK cell resistance and investigating NK cell adaptive changes in primary myeloma samples at different disease stages … Continued

Immune cell contribution to drug-resistance in Multiple Myeloma

Utilizing longitudinal bone marrow samples from relapsed-refractory MM patients treated with Elotuzumab-Iberdomide-Dexamethasone (EId), the study aims to evaluate immunologic profiles and specific biomarkers such as IKZF1 in immune cells. The project has three specific aims: 1) to profile the immune system of MM patients before EId treatment to identify correlations with high-risk MM phenotypes, 2) … Continued

Spatial and temporal tumor genomic heterogeneity in extramedullary multiple myeloma and solitary plasmacytoma with minimal marrow involvement

To test the hypothesis that plasmacytomas can represent spatial and temporal clonal escape events, featuring distinct myeloma-defining genomic events characteristic of active disease, through the following specific aims: Aim 1. Compare genomic driver events in paired samples from patients with newly diagnosed solitary plasmacytoma (SP) with minimal marrow involvement versus newly diagnosed multiple myeloma (NDMM) … Continued

Systematic functional genomics characterization of 17p13(del) multiple myeloma

This project aims to systematically characterize the functional genomics of 17p13 deletion in multiple myeloma (MM). Aim 1 seeks to identify potential tumor suppressor genes (TSGs) within 17p13 that cooperate with TP53 loss, investigating if haploinsufficiency of these genes contributes to MM pathogenesis. Aim 2 aims to define therapeutic vulnerabilities in MM cells with 17p … Continued

Role of flow cytometry and especially its use in the definition of the measurable residual disease (MRD) in multiple myeloma

This project aims to develop a clinically useful method for monitoring treatment response in multiple myeloma (MM) by detecting circulating tumor cells in peripheral blood (PB) using next-generation flow cytometry. The proposed approach, called BLOOD-FLOW, involves optimizing immunomagnetic enrichment of circulating plasma cells from large PB volumes, achieving a limit of detection two logs more … Continued

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events